Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
Wolfgang Miesbach; Jacob Lund/LinkedIn
Jan 16, 2026, 06:05

Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:

”Mim8 and How to Define FVIII Bioequivalence: Significant New Laboratory Data.

In haemophilia A, an important unresolved issue is how much FVIII‑bioequivalent haemostatic activity FVIIIa‑mimetic bispecific antibodies provide at therapeutic levels.

A new study in RPTH Journal by Jacob Lund and co-authors addresses this using calibrated thrombin generation in severe haemophilia A platelet-poor plasma (FVIII <1 %).

Plasma was:
– Spiked with graded FVIII or with Mim8 5 µg/mL and an emicizumab sequence‑identical analogue (SIA) 50 µg/mL.
– Tested under multiple triggers: TF, FXIa, TF+FXIa and FIXa.
– Analysed by fitting FVIII dose–response curves and expressing Mim8/emicizumab‑SIA activity as FVIII in vitro bioequivalence (IU/dL) using peak thrombin, ETP and velocity index.

Results (1 pM TF, clinically relevant condition):

  • Approx. 3‑fold higher FVIII bioequivalence for Mim8: ≈42 IU/dL vs ≈14 IU/dL for emicizumab‑SIA.
  • Higher thrombin peak at low FIXa, suggesting stronger activity in early haemostasis and in paediatric settings with lower FIX levels.
  • Optimised FIXa binding increases FIXa proteolytic activity by >20,000‑fold vs native FIXa.

Critical remarks:

The study illustrates that FVIII “equivalence” of bispecific antibodies is highly dependent on thrombin generation assay design, particularly trigger type/intensity and the parameter selected, and that Mim8 shows higher in vitro FVIII bioequivalence than emicizumab‑SIA at clinically relevant concentrations.

Higher in vitro FVIII bioequivalence ≠ demonstrated superiority in clinical outcomes; FRONTIER2 Phase 3 reported excellent bleed protection, and the extent to which these laboratory differences translate into real‑world clinical benefit remains to be clarified.”

Read the full article here.

Article: Factor VIII in vitro bioequivalence of Mim8 haemostatic effect by thrombin generation assays

Authors: Jacob Lund, Mirella Ezban, Kasper Jensen, David Lillicrap

Wolfgang Miesbach on Jacob Lund's Study: How to Define FVIII Bioequivalence

Stay updated on all scientific advances with Hemostasis Today.

bleeding disorders David Lillicrap Emicizumab haemophilia Health Hematology Hemostasis Hemostasis News Hemostasis Today Jacob Lund Kasper Jensen Medicine Mim8 Mirella Ezban rpth Wolfgang Miesbach
NewsFeed